Hyloris Pharmaceuticals Sa · EURONEXT:HYL
Hyloris Pharmaceuticals Sa — Kepler Cheuvreux Digital Life Science Day 2021
17 slides from Hyloris Pharmaceuticals Sa's conference presentation, Jun 22, 2021
Slide 1: Reformulating the Future
Reformulating the Future Kepler Cheuvreux Digital Life Science Day 22 June 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation has been prepared by, and is the sole responsibility of, Hyloris Pharmaceuticals SA (the "Company") for discussions with investors in relation to the Company and its group. For the purposes of this notice, “presentation” means this document, oral presenta
Slide 3: High Unmet Medical Needs
15,000 drugs in development in 2018 60 hit the market in 2018 High Unmet Medical Needs Pharmaprojects 2019 2
Slide 4: We do things differently
We do things differently 3
Slide 5: Rethinking, Reinventing, Optimising Existing Medications
Rethinking, Reinventing, Optimising Existing Medications To improve overall therapy outcomes REFORMULATING Changing dose or mode of administration REPURPOSING Finding new indications For the benefit of patients, physicians, payors 4
Slide 6: Hyloris: Potential Game Changer
Hyloris: Potential Game Changer Growth Pillars 11 patented product 2 products on the market with Patients, partners, physicians candidates in the pipeline partners and KOLs Spread across stages and Build own, lean, U.S. Real-world data and payors’ indications commercial team input Expand with 4 prod
Slide 7: Patented Value-Added Medicines: Pharma's Sweet Spot
Patented Value-Added Medicines: Pharma’s Sweet Spot To improve therapy outcomes New Chemical Unique Features Entities & Biologicals Reformulating, repurposing, combinations Patented value-added medicines: Optimised existing medicines Convenience, efficacy, tolerability, Off-patent compliance, onset
Slide 8: Faster Innovation at Much Lower Costs and Risks
Faster Innovation at Much Lower Costs and Risks Discovery, pre- Regulatory clinical Clinical Development submission & development decision 15 YEARS ON AVERAGE “Traditional Pharma-Biotech Model” $1.3 BILLION COSTS ON AVERAGE Feasibility, Regulatory Clinical formulation, submission & Development produ
Slide 9: Putting Healthcare Needs at the Centre of Therapy Design
Putting Healthcare Needs at the Centre of Therapy Design UNMET MEDICAL NEEDS 8
Slide 10: To Drive Continuous Growth and Create Shareholders' Value
To Drive Continuous Growth and Create Shareholders’ Value BUILD THE PIPELINE ADDRESSING NEEDS • Physicians’ input • Fast market adoption Technical feasibility UNMET • Well-known molecules MEDICAL • Clear regulatory pathway • Maximised ROI ≤ 7 years to market NEEDS • Patent protection ≤ €7 million co
Slide 11: Broad, Innovative Portfolio: Expand to ~30 Assets by 2024
Broad, Innovative Portfolio: Expand to ~30 Assets by 2024 Formulation and Clinical Regulatory Expected Product RoA Indication Manufacturing Development Filing Launch CARDIOVASCULAR (CV) PORTFOLIO Maximum 7 years on average Sotalol IV IV Atrial fibrillation Launched in U.S./partnered with AltaThera ’
Slide 12: Sourcing Product Opportunities Via Multiple Channels
Sourcing Product Opportunities Via Multiple Channels 11 PRODUCT CANDIDATES 2 COMMERCIAL PRODUCTS KOL / PARTNER ACQUISITION AND NETWORK IN-LICENSING DESK RESEARCH REAL WORLD DATA AND SURVEYS FDA-APPROVABLE OFF-LABEL USE 11
Slide 13: Powerful R&D Engine: Leveraging our Network of Partners
Powerful R&D Engine: Leveraging our Network of Partners Development cost-to-market (≤ €7M*) Commercialisation In-house Outsourced Commercial manufacturing Regulatory Product interactions selection Product development API sourcing Time-to-market (≤ 7 years) Note: bubble size indicates relative amount
Slide 14: 2020 has Set Strong Foundations for Value-Creation
2020 has Set Strong Foundations for Value-Creation R&D - Regulatory Commercial Corporate • Sotalol IV: U.S. approval • Raised €79.54M expanded label Maxigesic IV: • Strengthened management • Maxigesic IV: approvals in 17 EU team countries; Phase 3 completed • Licensed in >100 countries • Further bui
Slide 15: Core Assets: Anticipated Value Inflection Milestones in 2021
Core Assets: Anticipated Value Inflection Milestones in 2021 Clinical Regulatory Commercial HY-004: start Phase 1 Tranexamic Acid RTU: marketing Partnership Purna Female application in U.S. Healthcare • Atomoxetine: start + results pivotal Maxigesic IV: distribution • Maxigesic IV: marketing applica
Slide 16: Hyloris: Potential Game Changer, Geared for Growth
Hyloris: Potential Game Changer, Geared for Growth MULTIPLE SHOTS ON GOAL COMMERCIAL PORTFOLIO ≤ 7 Years to Market 2 patented products with partners ≤ €7 million Cost to Market Addressing unmet needs Lower risk as we start from Build U.S. commercial team existing drugs 14 approved products by 2024 I
Slide 17: investorrelations@hyloris.com
investorrelations@hyloris.com \ 16
Hyloris Pharmaceuticals — Kepler Cheuvreux Digital Life Science Day 2021 on 6ix